Bormioli Pharma is also collaborating with IMEM-CNR on a treatment to make type II glass bottles more resistant
Bormioli Pharma has announced several research and innovation projects to improve the performance and sustainability of its pharmaceutical glass products. The projects will involve collaborations with research centres, universities and start-ups, combined with the company’s own internal resources.
IMEM-CNR, a dedicated glass research centre, will be funded for a three-year PhD scholarship to investigate the development of performance-enhancing glass coatings.
To improve glass performance, the company is also collaborating with CNR on a treatment to make type II glass bottles more resistant, ensuring greater stability of the pharmaceutical formulations within.
With an eye to sustainability, Bormioli has joined Glass Future, a project aiming to develop a low CO2 emission approach to glass production. Experimentation and application of these technologies will be carried out at a pilot furnace in the UK.
The company has committed to manufacturing 50% of its products using materials with low environmental impact by 2025. It will also publish an integrated report measuring its performance against environmental, social and governmental parameters in H1 2022.
"In a celebration year for glass, we are ready to confirm our role as innovators in the industry, with several concrete research and development initiatives," said Andrea Lodetti, CEO of Bormioli Pharma. "This commitment is all the more important in a sector such as pharmaceuticals, where glass must not only contain, but also protect the therapeutic efficacy, and where the constant increase in production requires a serious rethinking of our responsibilities towards the environment."